Topical minoxidil is an FDA-approved treatment for male and female pattern hair loss, also known as androgenic alopecia (AGA).
Despite its popularity, not very many people continue using topical minoxidil for the long-run. In fact, one clinical study found that by the one-year mark, 95% of topical minoxidil users voluntarily quit applying the drug – with more than 2/3rds of them citing “low effect” as their rationale.[1]https://pubmed.ncbi.nlm.nih.gov/17917938/
So, what sort of hair regrowth can we expect from minoxidil? Why do so many people quit using the topical? And what can we do to maximize minoxidil’s hair growth-promoting effects, and in doing so, set ourselves up for sustainable hair regrowth years into the future?
What Is Minoxidil?
Topical minoxidil is the only medication approved by the FDA for the treatment of androgenic alopecia (AGA) in both males and females. Since its use as an anti-hypertensive drug in 1979, researchers have long-noted a nearly universal “adverse event” in oral minoxidil users: unexpected new hair growth along the limbs, chest, face, and scalp.[2]https://pubmed.ncbi.nlm.nih.gov/7030707/
This led to to the reformulation of minoxidil as a topical, and subsequent clinical trials to test its efficacy on treating AGA. In 1988 and 1992, 5% and 2% minoxidil became commercial available as an over-the-counter hair growth treatment for men and women, respectively.
How Does Minoxidil Work?
Researchers aren’t totally sure how minoxidil regrows hair.
Having said that, they suspect that minoxidil may work through at least one (or all) of the following mechanisms:
- Opening potassium ion channels – which increases blood, oxygen, and nutrient transport to balding regions (i.e., increased microcirculation)
- Modulation of prostaglandin analogues (i.e., decreased inflammation)
- Anti-androgenic activity in hair follicle sites (i.e., decreased dihydrotestosterone (DHT) – the hormone causally linked to baldness).
How Much Regrowth Should We Expect From Minoxidil?
For more information on these topics, see this article: Minoxidil: How Long Do Results Last (Even After Quitting)?
To summarize from the above, topical minoxidil has a response rate of just 40-60%. This is because a large number of users lack enough skin activity of an enzyme known as sulfotransferase – which is used to turn minoxidil into minoxidil sulfate, where the drug can then become active, attach to hair follicle sites, and have a positive impact on hair parameters.
But even with these poor response rates, 2% to 5% topical minoxidil still can improve hair weights by 20-30% over a 52-week period – and lead to modest hair count improvements – a portion of which will lead to cosmetically significant improvements to hair.
This is because the 40-60% of people who do respond to topical minoxidil tend to respond relatively robustly.
Factors affecting minoxidil’s response rates and regrowth rates are person-specific, and depend on (at least) the following:
- The person. Age, gender, hair loss severity, and genetic variations in the SULT1A1 gene
- The drug. Delivery methods (i.e., topical versus oral), along with dosing amounts and schedules (i.e., 5% twice-daily)
- Minoxidil enhancers. Whether minoxidil is used alongside therapies that enhance skin penetration and/or sulfotransferase activity (i.e., retinoic acid and/or microneedling)
This begs the question: if we’re worried we may not respond to minoxidil, how can we enhance the drug’s efficacy?
Fortunately, there are a number of ways to take someone from a non-responder to a great responder.
How Can Minoxidil Results Be Improved?
Rob English is a researcher, medical editor, and the founder of perfecthairhealth.com. He acts as a peer reviewer for scholarly journals and has published five peer-reviewed papers on androgenic alopecia. He writes regularly about the science behind hair loss (and hair growth). Feel free to browse his long-form articles and publications throughout this site.
References
↑1 | https://pubmed.ncbi.nlm.nih.gov/17917938/ |
---|---|
↑2 | https://pubmed.ncbi.nlm.nih.gov/7030707/ |
↑3 | https://pubmed.ncbi.nlm.nih.gov/25112173/ |
↑4 | https://pubmed.ncbi.nlm.nih.gov/24283387/ |
↑5 | https://pubmed.ncbi.nlm.nih.gov/10534633/ |
↑6, ↑8 | https://pubmed.ncbi.nlm.nih.gov/12196747/ |
↑7, ↑9 | https://pubmed.ncbi.nlm.nih.gov/2180995/ |